Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

ACTIVE NOT RECRUITING

Identifier: CI-TRIAL-00106205
Entity page: /trial/NCT04387084 ↗
Edges: 12

Neighbours: 1 cancers10 drugs
Drawn: 11 of 11 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy condition of …CONDITION_OFderived2 of 2
← condition of	Malignant Skin Neoplasm registry condition “Advanced Malignant Skin Neoplasm” mapped CURATED_BROADER	—	—	Malignant Skin Neoplasm	1	Observed	clinicaltrials	graph →
← condition of	Malignant Skin Neoplasm registry condition “Metastatic Malignant Skin Neoplasm” mapped CURATED_BROADER	—

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy intervention of …INTERVENTION_OFderived10 of 10
← intervention of	Atezolizumabmonoclonal antibody registry intervention “Atezolizumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Avelumabmonoclonal antibody registry intervention “Avelumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cemiplimabmonoclonal antibody registry intervention “Cemiplimab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Dostarlimabmonoclonal antibody registry intervention “Dostarlimab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Durvalumabmonoclonal antibody registry intervention “Durvalumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Nivolumabmonoclonal antibody registry intervention “Nivolumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pembrolizumabmonoclonal antibody registry intervention “Pembrolizumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Retifanlimabmonoclonal antibody registry intervention “Retifanlimab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Tislelizumabmonoclonal antibody registry intervention “Tislelizumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Toripalimabmonoclonal antibody registry intervention “Toripalimab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy intervention of …INTERVENTION_OFderived10 of 10

← intervention of

Atezolizumabmonoclonal antibody

registry intervention “Atezolizumab” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Avelumabmonoclonal antibody

registry intervention “Avelumab” (DRUG) mapped ALIAS

—